The Center for Biosimilars® recaps the top news for the week of January 14, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 14.
Number 5: A recently published study found that shifting reimbursement of some Medicare Part B drugs to Medicare Part D could increase out-of-pocket spending for some Medicare beneficiaries.
Number 4: Two studies published earlier this month found that biosimilar infliximab, CT-P13, had positive safety and efficacy data when switching patients with inflammatory bowel disease to the biosimilar.
Number 3: The House Committee on Oversight and Reform has launched a wide-ranging investigation into prescription drug pricing in the United States.
Number 2: In an interview with The Center for Biosimilars®, partners at Goodwin explained the impact that biosimilar developers will feel from the ongoing government shutdown.
Number 1: A representative from Pfizer has confirmed to The Center for Biosimilars® that the company has terminated 5 of its preclinical biosimilar programs after the results of the company’s annual investment review.
Finally, last week, our e-newsletter asked if the current administration is doing enough to curb cost growth for pharmaceuticals.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.